Filing Flows › Citius Oncology (CTOR) › Stock forecast & fair value
Citius Oncology (CTOR) stock forecast and price target
Citius Oncology (CTOR) trades at $0.51. One analyst's price target is $4.00 (+685%).
Citius Oncology's latest quarter
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CTOR stock?
One analyst's 12-month target is $4.00, +685% from $0.51. The average rating is buy.
Does Citius Oncology usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is CTOR stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.